Syntax Research’s Teladoc Health TDOC Stock Holding History

Syntax Research’s Portfolio TDOC Stock Details TDOC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-100	Closed	-$909	–	184
2024 Q4	$909	Hold	100	–	–	﹤0.01%	181
2024 Q3	$918	Hold	100	–	–	﹤0.01%	185
2024 Q2	$978	Buy	+100	New	+$1.22K	﹤0.01%	170

Other funds holding TDOC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MRCP

Maple Rock Capital Partners Toronto, Ontario, Canada $3.07B AUM 157.2% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Syntax Research's TDOC Position: Q1 2025 in Review

Syntax Research sold out of Teladoc Health (TDOC) in Q1 2025, closing a stake of 100 shares — an estimated $909 sold.

Syntax Research first reported a position in TDOC in Q2 2024 and held it in 3 quarters. The position peaked at $978 in Q2 2024. 383 funds tracked by Wall St. Rank hold TDOC as of Q1 2025.

Syntax Research reported no remaining Teladoc Health position as of Q1 2025 after selling out during the quarter.
Syntax Research sold 100 Teladoc Health shares in Q1 2025, an estimated $909.
Syntax Research first reported a position in Teladoc Health in Q2 2024 and held it in 3 quarters.
Syntax Research's Teladoc Health position peaked at $978 in Q2 2024.
383 funds tracked by Wall St. Rank held Teladoc Health as of Q1 2025.

Based on Syntax Research's 13F filing for Q1 2025, filed 7 May 2025.